

are often significantly debilitated when they develop co-existent *Aspergillus* lung disease. They can present with worsening breathlessness, weight loss and significant haemoptysis. There is no consensus on how to best treat patients diagnosed with Sarcoid and CPA.

Methods A retrospective review of patients diagnosed with Sarcoidosis and CPA was performed. Cases were identified from a database held of patients diagnosed with CPA group in our specialist clinic. Patient demographics, presentation, laboratory parameters, radiology results were recorded and data analysed.

Results 38 patients with sarcoidosis were diagnosed with CPA from 2009 – March 2015. 23/36 (63%) were male. 14/36 (38%) patients were affected by breathlessness with MRC dyspnoea score ≥ 3 . 15/36 (41%) of patients were on maintenance Prednisolone between 5 – 10 mg/day and 3 patients on other steroid sparing agents. 12/28 patients had obstructive spirometry and average predicted gas transfer factor at 49% (range 20 – 75%).

33/36 (91%) had CPA defined by presence of serum precipitins and 50% of patients had aspergillomas detected in the cavities on radiology. 27/36 (75%) of patients were on antifungal therapy. On regular follow-up, antifungal therapy was titrated based on serum azole levels and as tolerated.

4/36 (11%) patients had been treated for proven TB and 2/36 were on empirical treatment until TB diagnosis was excluded when there was clinical and radiological deterioration.

Conclusions Although sarcoidosis has slight female predominance, in this cohort of patients with CPA and sarcoid 63% were males. Many of the patients had significant lung disease with high MRC dyspnoea scores, and obstructive spirometry often with low gas transfers. The management of CPA in the setting of sarcoidosis is complex due to the risk of immunosuppression and interactions with antifungal therapy. Close working between specialties is important in optimising such patients, to ensure the best patient outcomes.

P35 IDENTIFYING NOVEL PREDICTORS OF OUTCOME IN SARCOIDOSIS

P Minnis, M Poland, G Nolan, SC Donnelly. *Department of Respiratory Medicine, Trinity Centre for Health Sciences, Tallaght Hospital, Dublin, Ireland*

10.1136/thoraxjnl-2015-207770.172

Background and objectives Sarcoidosis is a multisystem disease of unknown aetiology characterised by a Th1 granulomatous immune response. Predicting need for treatment in sarcoidosis is based on well-recognised prognostic indicators.¹ We aimed to interrogate a large cohort of sarcoidosis patients in order to identify novel predictors for treatment and disease progression defined physiologically and radiologically.

Methods Clinical data from 338 patients with sarcoidosis was recorded retrospectively including; age at diagnosis, gender, Scadding CXR stage at presentation, presence of Erythema Nodosum (EN), baseline inflammatory markers, immunoglobulin levels, skin prick testing (SPT), pulmonary function tests, BAL results and vitamin D levels. There was a minimum follow up of 2 years for all patients. The primary outcome measure was the need for treatment, defined as requiring oral corticosteroids for 6 months or more. Secondary outcome measures included need for steroid sparing agents and progression defined radiologically using scadding criteria or HRCT when available and assessing pulmonary function test decline.

Results Multivariate analysis and modelling of all presenting features was performed. Patients were characterised into four groups-limited no treatment, limited requiring steroids, chronic but stable and chronic progressive steroid dependent. Overall the treatment rate was 50.4% in this cohort. In the chronic cohort 32% required steroid sparing agents. Initial analysis confirmed previously known prognostic indicators including Scadding CXR stage, age >40 and presence of EN OR 0.24 (0.13–0.45), $p < 0.0001$ at diagnosis. Additional predictors of prognosis included IgG levels, positive skin prick testing and vitamin D levels. In the group with elevated levels of IgG (IQR 15.7–19.8) at assessment the treatment rate was 77.1% OR 3.3 (1.5 to 7.6) p value 0.004. In the group with positive SPT, only 17.4% required treatment, OR 0.21 (0.07–0.62), p value 0.005.

Conclusions These results indicate possible new markers of prognosis in terms of treatment and disease progression in sarcoidosis. Phenotyping sarcoid patients in this way may be valuable in designing future clinical trials in sarcoidosis.

REFERENCE

- 1 Neville E, Walker AN, Geraint James D. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. *QJM* 1983;4:525–533

P36 ETHNIC DIFFERENCES IN COMPOSITE PHYSIOLOGIC INDEX (CPI) IN PULMONARY SARCOIDOSIS: A 10-YEAR EXPERIENCE IN A SPECIALIST SARCOIDOSIS CLINIC

¹T Tully, ¹J Galloway, ²J Lally, ¹E Silber, ¹P Brex, ¹S Walsh, ¹G Larkin, ¹J Barker, ¹S Biring. ¹Kings College Hospital NHS Foundation Trust, London, UK; ²Kings College London, London, UK

10.1136/thoraxjnl-2015-207770.173

Introduction and objectives CPI has been reported to be an accurate predictor of mortality in sarcoidosis and IPF. A CPI score of >40 is associated with a 5 year survival probability of 50%.¹ There is a paucity of studies of CPI in patients of black ethnicity. We investigated CPI in a large cohort of patients attending a specialist sarcoidosis clinic serving a large African Caribbean community in South-East London.

Methods 503 subjects with a diagnosis of sarcoidosis were assessed between May 2005 and May 2015. Relevant data needed to calculate CPI and ethnicity information was available in 297 patients with pulmonary involvement (based on radiological evidence +/- histological evidence). We calculated CPI with the following formula: $91.0 - (0.65 \times \text{percent predicted DLCO}) - (0.53 \times \text{percent predicted FVC}) + (0.34 \times \text{percent predicted FEV1})$. Clinical demographics, organ involvement, lung function, histology and subsequent therapy were systematically recorded (Table 1).

Results There were significant differences in CPI between all ethnic groups (ANOVA, $p < 0.001$). Black patients had a higher mean CPI score compared to white patients (39.0 (14.2) vs 29.9 (18.5), $t = -4.129$, $p < 0.001$) (Table 1). CPI was significantly higher in black Caribbean patients versus black African patients (41.2 (14.4) vs 36.3 (13.7), $t = 2.656$ $p = 0.008$). CPI was weakly correlated with number of immunosuppressant medications used; correlation coefficient $r = 0.214$, $p < 0.001$. CPI was not associated with age at presentation, gender, initial requirement of treatment or prediction of ≥ 2 -organ involvement.

Conclusion Black patients have more severe disease than other ethnicities, with the most severe illness in those of black Caribbean ethnicity, who have the worst CPI scores. Further studies